|
목적 : To evaluate the therapeutic effects and safety of oral spironolactone(SPRL) in the patients with central serous chorioretinopathy(CSC).
방법 : The medical records and imaging data from consecutive patients diagnosed as CSC and treated with SPRL were reviewed. Changes in central macular thickness(CMT), subretinal fluids(SRF), subfoveal choroidal thickness(SFCT), best corrected visual acuity(BCVA) at baseline, 1,3 and 6months after using medication were included in outcome measures. The patients were classified into 3 groups as complete responder, partial responder and non-responder. Each group was compared by the outcome measures above. The occurrence of side effects and recurrence after complete resolution of SRF were also assessed.
결과 : 104 patients with 108 eyes were included. CMT, SRF, SFCT after using SPRL improved significantly at 1, 3, 6months and at last follow up, but BCVA showed no significant change at all points. 13%, 33.3%, 51.7% showed complete resolution of SRF at 1,3 and 6months, respectively, and 13% experienced recurrence after complete resolustion. complete resolution group showed significant difference with partial and non-resolution group at 6months and last visit. 2 male patients experienced gynecomastia, 1 patients experienced alopecia and 1 patient showed mild elevation of serum creatinine level.
결론 : Our study showed therapeutic benefits in patients with CSC, especially in anatomical structures. But careful observation should be needed, because of several side effects and recurrence after complete resolution.
|